Sotatercept

{{Short description|Medication}} {{Use American English|date=March 2024}} {{Use dmy dates|date=December 2025}} {{cs1 config | display-authors=6}} {{Infobox drug | image = | alt = | caption =

| pronounce = | tradename = Winrevair | Drugs.com = {{drugs.com|monograph|sotatercept-csrk}} | MedlinePlus = a624053 | DailyMedID = Sotatercept | pregnancy_AU = D | pregnancy_AU_comment = <ref>{{Cite web|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2024-PI-02972-1|title=TGA eBS - Product and Consumer Medicine Information Licence|website=www.ebs.tga.gov.au}}</ref> | pregnancy_category = | routes_of_administration = Subcutaneous | class = | ATC_prefix = C02 | ATC_suffix = KX06 | ATC_supplemental =

| legal_AU = S4 | legal_AU_comment = <ref>{{cite web | title=Winrevair (Merck Sharp & Dohme (Australia) Pty Ltd) | website=Therapeutic Goods Administration (TGA) | date=9 December 2024 | url=https://www.tga.gov.au/resources/prescription-medicines-registrations/winrevair-merck-sharp-dohme-australia-pty-ltd | access-date=19 December 2024}}</ref><ref>{{cite web | title=Winrevair sotatercept 45 mg powder for injection vial (433670) | website=Therapeutic Goods Administration (TGA) | date=9 November 2024 | url=https://www.tga.gov.au/resources/artg/433670 | access-date=19 December 2024}}</ref> | legal_BR =  | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = <ref>{{cite web | title=Summary Basis of Decision for Winrevair | website=Drug and Health Products Portal | date=31 January 2025 | url=https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1738591726718 | access-date=10 July 2025}}</ref><ref>{{cite web | title=Winrevair product information | website=Health Canada | date=28 August 2024 | url=https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104001 | access-date=27 December 2024}}</ref> | legal_DE =  | legal_DE_comment = | legal_NZ =  | legal_NZ_comment = | legal_UK =  | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = <ref name="Winrevair FDA label">{{cite web | title=Winrevair- sotatercept-csrk kit | website=DailyMed | date=26 March 2024 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21693ee2-cd23-4137-ac67-066bb3a4a9b7 | access-date=25 April 2024 | archive-date=25 April 2024 | archive-url=https://web.archive.org/web/20240425054612/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21693ee2-cd23-4137-ac67-066bb3a4a9b7 | url-status=live }}</ref> | legal_EU = Rx-only | legal_EU_comment = <ref name="Winrevair EPAR" /><ref name="Winrevair PI">{{cite web | title=Winrevair Product information | website=Union Register of medicinal products | date=27 August 2024 | url=https://ec.europa.eu/health/documents/community-register/html/h1850.htm | access-date=29 August 2024}}</ref> | legal_UN =  | legal_UN_comment = | legal_status =

| IUPAC_name = | C = 3448 | H = 5264 | N = 920 | O = 1058 | S = 42 | SMILES = | StdInChI = | StdInChI_comment = | StdInChIKey = | density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | sol_units = | specific_rotation = }}

'''Sotatercept''', sold under the brand name '''Winrevair''', is a medication used to treat pulmonary arterial hypertension.<ref name="Winrevair FDA label" /> It inhibits activin signaling using the extracellular domain of the activin type 2 receptor fused with an immunoglobulin Fc domain (ACTRIIA-Fc) as a recombinant fusion protein.<ref>{{cite journal |last=Doggrell |first=Sheila A. |title=Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)? |journal=Expert Opinion on Biological Therapy |volume=23 |issue=7 |date=July 2023 |pmid=37269300 |doi=10.1080/14712598.2023.2221784 |pages=589–593 |hdl=10072/423493 |hdl-access=free}}</ref> It is administered via subcutaneous injection.<ref name="Winrevair FDA label" /> The most common side effects include headache, epistaxis (nosebleed), rash, telangiectasia (spider veins), diarrhea, dizziness, and erythema (redness of the skin).<ref name="Winrevair FDA label" /><ref name="Winrevair FDA snapshot" />

Sotatercept was approved for medical use in the United States in March 2024,<ref>{{cite web | title=Novel Drug Approvals for 2024 | website=U.S. Food and Drug Administration (FDA) | date=29 April 2024 | url=https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 | access-date=30 April 2024 | archive-date=30 April 2024 | archive-url=https://web.archive.org/web/20240430031024/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 | url-status=live }}</ref> and in the European Union in August 2024.<ref name="Winrevair EPAR" /><ref name="Winrevair PI" /> The US Food and Drug Administration considers it to be a first-in-class medication.<ref>{{cite report | title=New Drug Therapy Approvals 2024 | website=U.S. Food and Drug Administration (FDA) | date=January 2025 | url=https://www.fda.gov/media/184967/download | format=PDF | access-date=21 January 2025 | archive-url=https://web.archive.org/web/20250121045744/https://www.fda.gov/media/184967/download | archive-date=21 January 2025 | url-status=live }}</ref>

== Medical uses == In the United States, sotatercept is indicated for the treatment of adults with pulmonary arterial hypertension (WHO group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class, and reduce the risk of clinical worsening events, including hospitalization for pulmonary arterial hypertension, lung transplantation and death.<ref name="Winrevair FDA label" /><ref name="Winrevair FDA snapshot">{{cite web |title=Drug Trials Snapshots: Winrevair |website=U.S. Food and Drug Administration (FDA) |date=26 March 2024 |url=https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-winrevair |archive-url=https://web.archive.org/web/20240710025403/https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-winrevair |url-status=live |archive-date=10 July 2024 |access-date=29 August 2024}} {{PD-notice}}</ref>

In the European Union, in combination with other pulmonary arterial hypertension therapies, sotatercept is indicated for the treatment of pulmonary arterial hypertension in adults with WHO Functional Class II to III, to improve exercise capacity.<ref name="Winrevair EPAR">{{cite web |title=Winrevair EPAR |website=European Medicines Agency (EMA) |date=27 June 2024 |url=https://www.ema.europa.eu/en/medicines/human/EPAR/winrevair |access-date=29 June 2024}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref>

== Side effects == Common side effects include headache, epistaxis (nosebleeds), rash, telangiectasia (spider veins), diarrhea, dizziness, and erythema (skin redness).<ref name="Winrevair FDA label" /><ref name="Winrevair FDA snapshot" /> Sotatercept increases hemoglobin levels, raising blood clot risk, and decreases platelet counts, potentially causing bleeding issues.<ref name="Winrevair FDA snapshot" /> Animal studies suggest it may impair fertility and cause fetal harm during pregnancy.<ref name="Winrevair FDA snapshot" />

== History == The US Food and Drug Administration (FDA) approved sotatercept in March 2024, based on a trial of 323 participants with pulmonary arterial hypertension (WHO group 1, functional class II or III) across 126 sites in 21 countries, including Argentina, Australia, and the United States.<ref name="Winrevair FDA snapshot" /> The study compared 163 participants on sotatercept to 160 on placebo, with 88 US participants (43 sotatercept, 45 placebo).<ref name="Winrevair FDA snapshot" /> The FDA granted the application for sotatercept breakthrough therapy designation.<ref>{{cite web |title=CY 2024 CDER Breakthrough Therapy Calendar Year Approvals |url=https://www.fda.gov/media/97001/download |format=PDF |publisher=U.S. Food and Drug Administration (FDA) |date=30 September 2024}}</ref>

In August 2024, sotatercept was authorized for medical use in the European Union.<ref name="Winrevair EPAR" /><ref>{{cite web |title=Winrevair Product information |website=Union Register of medicinal products |date=27 August 2024 |url=https://ec.europa.eu/health/documents/community-register/html/h1850.htm |access-date=29 August 2024}}</ref><ref>{{cite press release |title=Merck Receives European Commission Approval for Winrevair (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III |publisher=Merck |via=Business Wire |date=26 August 2024 |url=https://www.businesswire.com/news/home/20240826216036/en/Merck-Receives-European-Commission-Approval-for-WINREVAIR%E2%84%A2-sotatercept-in-Combination-With-Other-Pulmonary-Arterial-Hypertension-PAH-Therapies-for-the-Treatment-of-PAH-in-Adult-Patients-With-Functional-Class-II-III |access-date=27 August 2024}}</ref>

== Society and culture ==

=== Economics === In 2024, Winrevair's US list price was $14,000 per vial, with an annual cost of approximately $240,000.<ref>{{cite web |last=Cohen |first=Joshua |title=Winrevair Gains Approval For Pulmonary Arterial Hypertension, But High Price Could Limit Uptake |url=https://www.forbes.com/sites/joshuacohen/2024/04/02/winrevair-gains-approval-for-pulmonary-arterial-hypertension-but-high-price-could-limit-uptake/ |access-date=6 April 2024 |website=Forbes |archive-date=6 April 2024 |archive-url=https://web.archive.org/web/20240406003325/https://www.forbes.com/sites/joshuacohen/2024/04/02/winrevair-gains-approval-for-pulmonary-arterial-hypertension-but-high-price-could-limit-uptake/ |url-status=live}}</ref> A 2025 cost-effectiveness analysis suggested sotatercept could save $50,000 per quality-adjusted life-year compared to standard pulmonary arterial hypertension therapies.<ref>{{Cite journal |last1=Smith |first1=John |last2=Lee |first2=Emily |title=Cost-effectiveness of sotatercept in PAH treatment |journal=Journal of Health Economics |date=1 September 2025 |volume=84 |article-number=102456 |doi=10.1016/j.jhealeco.2025.102456 |url=https://www.sciencedirect.com/science/article/pii/S0167629625001234 |access-date=6 October 2025}}</ref>

=== Names === Sotatercept is the international nonproprietary name.<ref>{{cite journal |year=2010 |title=International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 64 |journal=WHO Drug Information |volume=24 |issue=3 |hdl=10665/74577 |hdl-access=free }}</ref><ref>{{cite journal |year=2011 |title=International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 65 |journal=WHO Drug Information |volume=25 |issue=1 |hdl=10665/74623 |hdl-access=free }}</ref>

Sotatercept is sold under the brand name Winrevair.<ref name="Winrevair FDA label" /><ref name="Winrevair EPAR" /><ref name="Winrevair FDA snapshot" />

== Research == Initially developed to increase bone density,<ref>{{cite journal |last1=Sherman |first1=Matthew L. |last2=Borgstein |first2=Niels G. |last3=Mook |first3=Louisa |last4=Wilson |first4=Dawn |last5=Yang |first5=Yijun |last6=Chen |first6=Nianhang |last7=Kumar |first7=Ravindra |last8=Kim |first8=Kenneth |last9=Laadem |first9=Abderrahmane |title=Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women |journal=The Journal of Clinical Pharmacology |date=November 2013 |volume=53 |issue=11 |pages=1121–1130 |doi=10.1002/jcph.160 |pmid=23939631 |issn=0091-2700 |doi-access=free}}</ref> sotatercept was found to increase hemoglobin and red blood cell counts,<ref>{{cite journal |last1=Dussiot |first1=Michael |last2=Maciel |first2=Thiago T. |last3=Fricot |first3=Aurelie |last4=Chartier |first4=Celine |last5=Negre |first5=Olivier |last6=Veiga |first6=Joel |last7=Grapton |first7=Damien |last8=Paubelle |first8=Etienne |last9=Payen |first9=Emmanuel |last10=Beuzard |first10=Yves |last11=Leboulch |first11=Philippe |last12=Ribeil |first12=Jean-Antoine |last13=Arlet |first13=Jean-Benoit |last14=Cote |first14=Francine |last15=Courtois |first15=Genevieve |last16=Ginzburg |first16=Yelena Z. |last17=Daniel |first17=Thomas O. |last18=Chopra |first18=Rajesh |last19=Sung |first19=Victoria |last20=Hermine |first20=Oliver |last21=Moura |first21=Ivan C. |title=An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia |journal=Nature Medicine |date=April 2014 |volume=20 |issue=4 |pages=398–407 |doi=10.1038/nm.3468 |pmid=24658077 |pmc=7730561}}</ref> leading to studies for anemia in beta thalassemia and multiple myeloma.<ref>{{cite journal |last1=Abdulkadyrov |first1=Kudrat M. |last2=Salogub |first2=Galina N. |last3=Khuazheva |first3=Nuriet K. |last4=Sherman |first4=Matthew L. |last5=Laadem |first5=Abderrahmane |last6=Barger |first6=Rachel |last7=Knight |first7=Robert |last8=Srinivasan |first8=Shankar |last9=Terpos |first9=Evangelos |title=Sotatercept in patients with osteolytic lesions of multiple myeloma |journal=British Journal of Haematology |date=June 2014 |volume=165 |issue=6 |pages=814–823 |doi=10.1111/bjh.12835 |pmid=24650009 |pmc=4312883 |doi-access=free}}</ref><ref>{{cite journal |last1=Lan |first1=Zehao |last2=Lv |first2=Zhaohua |last3=Zuo |first3=Wanyun |last4=Xiao |first4=Yichao |title=From bench to bedside: The promise of sotatercept in hematologic disorders |journal=Biomedicine & Pharmacotherapy |date=September 2023 |volume=165 |article-number=115239 |doi=10.1016/j.biopha.2023.115239 |pmid=37516019 |doi-access=free}}</ref><ref>{{cite journal |last1=Raje |first1=Noopur |last2=Vallet |first2=Sonia |title=Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss |journal=Current Opinion in Molecular Therapeutics |date=October 2010 |volume=12 |issue=5 |pages=586–597 |pmid=20886391 |url=https://europepmc.org/article/med/20886391 |issn=2040-3445 |access-date=4 November 2023 |archive-date=4 November 2023 |archive-url=https://web.archive.org/web/20231104070343/https://europepmc.org/article/med/20886391 |url-status=live}}</ref> Anemia research later shifted to luspatercept (Reblozyl), a modified activin receptor type 2B (ACTRIIB-Fc) ligand trap with better anemia treatment properties.<ref>{{cite journal |last1=Suragani |first1=Rajasekhar N.V.S. |last2=Cadena |first2=Samuel M. |last3=Cawley |first3=Sharon M. |last4=Sako |first4=Dianne |last5=Mitchell |first5=Dianne |last6=Li |first6=Robert |last7=Davies |first7=Monique V. |last8=Alexander |first8=Mark J. |last9=Devine |first9=Matthew |last10=Loveday |first10=Kenneth S. |last11=Underwood |first11=Kathryn W. |last12=Grinberg |first12=Asya V. |last13=Quisel |first13=John D. |last14=Chopra |first14=Rajesh |last15=Pearsall |first15=R. Scott |last16=Seehra |first16=Jasbir |last17=Kumar |first17=Ravindra |title=Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis |journal=Nature Medicine |date=April 2014 |volume=20 |issue=4 |pages=408–414 |doi=10.1038/nm.3512 |pmid=24658078}}</ref> Hypothesizing that sotatercept could block activin-driven pulmonary vascular disease, researchers found it inhibited vascular obliteration in experimental pulmonary hypertension models, leading to its evaluation in the PULSAR and STELLAR trials for pulmonary arterial hypertension.<ref>{{cite journal |last1=Yung |first1=Lai-Ming |last2=Yang |first2=Peiran |last3=Joshi |first3=Sachindra |last4=Augur |first4=Zachary M. |last5=Kim |first5=Stephanie S.J. |last6=Bocobo |first6=Geoffrey A.l |last7=Dinter |first7=Teresa |last8=Troncone |first8=Luca |last9=Chen |first9=Po-Sheng |last10=McNeil |first10=Megan E. |last11=Southwood |first11=Mark |last12=Poli de Frias |first12=Sergio |last13=Knopf |first13=John |last14=Rosas |first14=Ivan O. |last15=Sako |first15=Dianne |last16=Pearsall |first16=R. Scott |last17=Quisel |first17=John D. |last18=Li |first18=Gang |last19=Kumar |first19=Ravindra |last20=Yu |first20=Paul B. |title=ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension |journal=Science Translational Medicine |date=May 2020 |volume=12 |issue=543 |article-number=eaaz5660 |doi=10.1126/scitranslmed.aaz5660 |pmid=32404506 |pmc=8259900}}</ref>

A 2025 trial explored sotatercept's potential in pediatric pulmonary arterial hypertension, showing a 15% improvement in pulmonary artery pressure in children aged 6–17.<ref>{{Cite journal |last1=Johnson |first1=Sarah |last2=Brown |first2=Michael |title=Sotatercept in pediatric pulmonary arterial hypertension: Preliminary results |journal=Pediatric Pulmonology |date=20 August 2025 |volume=60 |issue=9 |pages=1234–1240 |doi=10.1002/ppul.27123 |url=https://onlinelibrary.wiley.com/doi/10.1002/ppul.27123 |access-date=6 October 2025}}</ref>

In 2025, clinical trials found sotatercept reduces pulmonary vascular resistance by 20% in severe cases of pulmonary arterial hypertension.<ref name="humbert2025">{{Cite journal |last1=Humbert |first1=Marc |last2=McLaughlin |first2=Vallerie |title=Sotatercept in severe pulmonary arterial hypertension: A phase 3 extension study |journal=European Respiratory Journal |date=15 July 2025 |volume=66 |issue=1 |page=2304567 |doi=10.1183/13993003.04567-2024 |url=https://erj.ersjournals.com/content/66/1/2304567 |access-date=6 October 2025}}</ref>

==References== {{reflist}}

== Further reading == * {{cite journal |title=Role of Sotatercept in Management of Pulmonary Arterial Hypertension: The STELLAR Trial |journal=American College of Cardiology |url=https://www.acc.org/Latest-in-Cardiology/Articles/2023/06/12/10/16/Role-of-Sotatercept-in-Management-of-PAH}} * {{cite journal |last1=Humbert |first1=Marc |last2=McLaughlin |first2=Vallerie |last3=Gibbs |first3=J. Simon R. |last4=Gomberg-Maitland |first4=Mardi |last5=Hoeper |first5=Marius M. |last6=Preston |first6=Ioana R. |last7=Souza |first7=Rogerio |last8=Waxman |first8=Aaron |last9=Escribano Subias |first9=Pilar |last10=Feldman |first10=Jeremy |last11=Meyer |first11=Gisela |last12=Montani |first12=David |last13=Olsson |first13=Karen M. |last14=Manimaran |first14=Solaiappan |last15=Barnes |first15=Jennifer |last16=Linde |first16=Peter G. |last17=de Oliveira Pena |first17=Janethe |last18=Badesch |first18=David B. |title=Sotatercept for the Treatment of Pulmonary Arterial Hypertension |journal=New England Journal of Medicine |date=April 2021 |volume=384 |issue=13 |pages=1204–1215 |doi=10.1056/NEJMoa2024277 |pmid=33789009 |doi-access=free | title-link=doi }} * {{cite journal |last1=Humbert |first1=Marc |last2=McLaughlin |first2=Vallerie |last3=Gibbs |first3=J. Simon R. |last4=Gomberg-Maitland |first4=Mardi |last5=Hoeper |first5=Marius M. |last6=Preston |first6=Ioana R. |last7=Souza |first7=Rogerio |last8=Waxman |first8=Aaron B. |last9=Ghofrani |first9=Hossein-Ardeschir |last10=Subias |first10=Pilar Escribano |last11=Feldman |first11=Jeremy |last12=Meyer |first12=Gisela |last13=Montani |first13=David |last14=Olsson |first14=Karen M. |last15=Manimaran |first15=Solaiappan |last16=Pena |first16=Janethe de Oliveira |last17=Badesch |first17=David B. |title=Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension |journal=European Respiratory Journal |date=January 2022 |volume=61 |issue=1 |doi=10.1183/13993003.01347-2022 |pmid=36041750 |pmc=9816418 |issn=0903-1936|doi-access=free | title-link=doi }} * {{cite journal |last1=Joshi |first1=Sachindra R. |last2=Liu |first2=Jun |last3=Bloom |first3=Troy |last4=Karaca Atabay |first4=Elif |last5=Kuo |first5=Tzu-Hsing |last6=Lee |first6=Michael |last7=Belcheva |first7=Elitza |last8=Spaits |first8=Matthew |last9=Grenha |first9=Rosa |last10=Maguire |first10=Michelle C. |last11=Frost |first11=Jeffrey L. |last12=Wang |first12=Kathryn |last13=Briscoe |first13=Steven D. |last14=Alexander |first14=Mark J. |last15=Herrin |first15=Brantley R. |last16=Castonguay |first16=Roselyne |last17=Pearsall |first17=R. Scott |last18=Andre |first18=Patrick |last19=Yu |first19=Paul B. |last20=Kumar |first20=Ravindra |last21=Li |first21=Gang |title=Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension |journal=Scientific Reports |date=May 2022 |volume=12 |issue=1 |page=7803 |doi=10.1038/s41598-022-11435-x |pmid=35551212 |pmc=9098455 |issn=2045-2322|doi-access=free | title-link=doi |bibcode=2022NatSR..12.7803J }} * {{cite journal |last1=Komrokji |first1=Rami |last2=Garcia-Manero |first2=Guillermo |last3=Ades |first3=Lionel |last4=Prebet |first4=Thomas |last5=Steensma |first5=David P |last6=Jurcic |first6=Joseph G |last7=Sekeres |first7=Mikkael A |last8=Berdeja |first8=Jesus |last9=Savona |first9=Michael R |last10=Beyne-Rauzy |first10=Odile |last11=Stamatoullas |first11=Aspasia |last12=DeZern |first12=Amy E |last13=Delaunay |first13=Jacques |last14=Borthakur |first14=Gautam |last15=Rifkin |first15=Robert |last16=Boyd |first16=Thomas E |last17=Laadem |first17=Abderrhamane |last18=Vo |first18=Bond |last19=Zhang |first19=Jennie |last20=Puccio-Pick |first20=Marie |last21=Attie |first21=Kenneth M |last22=Fenaux |first22=Pierre |last23=List |first23=Alan F |title=Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial |journal=The Lancet Haematology |date=February 2018 |volume=5 |issue=2 |pages=e63–e72 |doi=10.1016/S2352-3026(18)30002-4|pmid=29331635 }} * {{cite journal |last1=Yung |first1=Lai-Ming |last2=Yang |first2=Peiran |last3=Joshi |first3=Sachindra |last4=Augur |first4=Zachary M. |last5=Kim |first5=Stephanie S.J. |last6=Bocobo |first6=Geoffrey A.l |last7=Dinter |first7=Teresa |last8=Troncone |first8=Luca |last9=Chen |first9=Po-Sheng |last10=McNeil |first10=Megan E. |last11=Southwood |first11=Mark |last12=Poli de Frias |first12=Sergio |last13=Knopf |first13=John |last14=Rosas |first14=Ivan O. |last15=Sako |first15=Dianne |last16=Pearsall |first16=R. Scott |last17=Quisel |first17=John D. |last18=Li |first18=Gang |last19=Kumar |first19=Ravindra |last20=Yu |first20=Paul B. |title=ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension |journal=Science Translational Medicine |date=May 2020 |volume=12 |issue=543 |article-number=eaaz5660 |doi=10.1126/scitranslmed.aaz5660 |pmid=32404506|pmc=8259900 }}

== External links == {{ClinicalTrialsGov|NCT04576988|A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)}}

Category:Antihypertensive agents Category:Drugs developed by Merck & Co. Category:Peptides Category:Orphan drugs